<DOC>
	<DOC>NCT01272362</DOC>
	<brief_summary>In this 5-months study, the response of patients to salbutamol at baseline will be compared with their response to treatment with indacaterol.</brief_summary>
	<brief_title>To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Diagnosis of COPD (moderatetosevere as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2009) and: 1. Postbronchodilator FEV1 &lt;80% and â‰¥30% of the predicted normal value 2. Postbronchodilator FEV1/FVC (forced vital capacity) &lt;70% Smoking history of at least 10 packyears Patients who have had a COPD exacerbation in the 6 weeks prior to screening Patients who have had a respiratory tract infection within 4 weeks prior to screening Patients with concomitant pulmonary disease Patients with a history of asthma Patients with diabetes Type I or uncontrolled diabetes Type II Any patient with lung cancer or a history of lung cancer Patients with a history of certain cardiovascular comorbid conditions Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Indacaterol</keyword>
	<keyword>COPD</keyword>
	<keyword>LABA</keyword>
	<keyword>Reversibility</keyword>
</DOC>